Form 483

King Bio Inc Form 483, 2023-07-28

FDA issued a Form 483 to King Bio Inc on 2023-07-28 with 2 public-safe observations.

483· Form 483 issuedHuman Drugs2 observations

King Bio Inc · Asheville, United States · Issued July 28, 2023

Overview

  • 2 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

28 Jul 2023
21 CFR 211.113(a)

Procedures for non-sterile drug products

Cited by Libia M Lugo

28 Jul 2023
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Libia M Lugo

Inspected site

KBKing Bio IncAsheville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 2 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere